secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0001493152-25-004501
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals converts $500k debt to equity at $1.50/share; licenses Dermytol skin care for 650k shares
--------------------------------------------------------------------------------

- Entered First Amendment with MAAB Global to convert $500,000 debt into up to 333,334 shares at $1.50/share.
- Signed Master Distribution Agreement with Propre Energie for Dermytol® formulations; pays 650,000 restricted shares and 1% gross sales revenue.
- Assigned rights under two Epiq Scripts agreements to subsidiary M&P; CEO Jacob Cohen is 51% owner of Epiq Scripts.
- Entered LT Global Practice Management Service Agreement (CEO's wife's company) for virtual professionals at $1,800-$3,500 each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225004501/0001493152-25-004501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225004501/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-004501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer